Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Virgin Galactic Holdings, Inc. trades at $2.59 (market cap $330.34M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 120.8× Virgin Galactic Holdings, Inc.'s market cap. Which is the better fit depends on your goals.
| ALNY | SPCE | |
|---|---|---|
Market Cap | $39.89B | $330.34M |
Sector | Health | Industrials |
52-Week High | $491.22 | $7.52 |
52-Week Low | $278.09 | $2.17 |
Enterprise Value | $38.15B | $430.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Virgin Galactic (SPCE) trades at $2.57, down 1.91% on the day, with a bearish technical signal from moving averages. The company continues to report significant losses with negative gross profit margins of -6,127.71% and net income margin of -19,781.3% for 2025. Recent news highlights volatility in space stocks following SpaceX's IPO, with SPCE experiencing sharp price swings. Cash flow remains negative at -$35.17 million for 2025, though showing improvement from previous years.
The outlook remains challenging with persistent operational losses and high cash burn. Investment opportunity exists if the company can achieve commercial scale and profitability, but risks include execution challenges, competitive pressure, and dependence on additional financing. Analyst consensus is divided with 29% buy, 41% hold, and 29% sell ratings, reflecting uncertainty about the company's path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
